PRESERVE: Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population
This study, initiated by AngioDynamics, Inc. in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), will evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. It will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.
PRESERVE is led by Co-Principal Investigators – Jonathan A. Coleman, MD, Urologist at Memorial Sloan Kettering Cancer Center and Arvin George, MD, Urologist at the University of Michigan.